Ignyta Company Profile (NASDAQ:RXDX)

About Ignyta (NASDAQ:RXDX)

Ignyta logoIgnyta, Inc. is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company's pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106. Entrectinib is an orally bioavailable, central nervous system (CNS)-active, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (TRK) family of tyrosine kinase receptors (TRKA, TRKB and TRKC), ROS1 and anaplastic lymphoma kinase (ALK) proteins. RXDX-105 is an orally bioavailable, vascular endothelial growth factor receptor (VEGFR)-sparing, small molecule tyrosine kinase inhibitor of rearranged during transfection (RET). Taladegib is an orally bioavailable, small molecule hedgehog/smoothened antagonist. RXDX-106 is a pseudo-irreversible, small molecule inhibitor of TYRO3, AXL and MER (collectively TAM), and c-MET.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RXDX
  • CUSIP: N/A
  • Web: www.ignyta.com
Capitalization:
  • Market Cap: $697.55 million
  • Outstanding Shares: 56,253,000
Average Prices:
  • 50 Day Moving Avg: $10.19
  • 200 Day Moving Avg: $8.96
  • 52 Week Range: $4.15 - $12.45
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.35
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $2.04 per share
  • Price / Book: 5.93
Profitability:
  • EBIDTA: ($114,260,000.00)
  • Return on Equity: -123.52%
  • Return on Assets: -75.75%
Debt:
  • Debt-to-Equity Ratio: 0.26%
  • Current Ratio: 7.30%
  • Quick Ratio: 7.31%
Misc:
  • Average Volume: 956,353 shs.
  • Beta: 2.02
  • Short Ratio: 4.57
 

Frequently Asked Questions for Ignyta (NASDAQ:RXDX)

What is Ignyta's stock symbol?

Ignyta trades on the NASDAQ under the ticker symbol "RXDX."

How were Ignyta's earnings last quarter?

Ignyta, Inc. (NASDAQ:RXDX) issued its earnings results on Tuesday, August, 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.63) by $0.07. View Ignyta's Earnings History.

Where is Ignyta's stock going? Where will Ignyta's stock price be in 2017?

2 analysts have issued 12-month price targets for Ignyta's shares. Their predictions range from $15.00 to $27.00. On average, they expect Ignyta's share price to reach $21.00 in the next year. View Analyst Ratings for Ignyta.

What are analysts saying about Ignyta stock?

Here are some recent quotes from research analysts about Ignyta stock:

  • 1. According to Zacks Investment Research, "Ignyta, Inc. is a biotechnology company. It develops precision medicine with integrated Rx/Dx solutions for cancer patients. The company focuses on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases. Ignyta, Inc. is based in San Diego, California. " (8/15/2017)
  • 2. Cantor Fitzgerald analysts commented, "Entrectinib in ROS1 Shows Strong Interim Data. RXDX reported interim data in 32 patients with ROS1 NSCLC from the Phase II STARTRK2 trial, with an ORR of 75% (24/32 patients) as of a 12/16 cutoff, with a median duration of treatment of 17.2 months (PFS of 19.1 months, 63% of patients still on study). Looks Competitive. There are other agents for ROS1 NSCLC, but we think entrectinib is a competitive contender among the ROS1 agents. Of note are across-the-board positive ORR and DOR in both TKI-naive patients with and without CNS metastases: 34% of the patients in the dataset had CNS lesions, and responses were observed in 7/11, an ORR of 64%. NDA Strategy, Top Line Data in 2018. In addition to the data release RXDX confirmed the filing strategy that will see two separate NDAs for ROS1 NSCLC and a potential molecular defined label (rather than tumor-specific) label for TRK alterations. We anticipate the completion of enrollment of both ROS1 and TRK arms in 3Q17, with top line data in 1H18 and NDA filings in that year. Clear Strategy, Other Assets. With FDA confirmed regulatory plans in hand, we think the definitive NDA roadmap for entrectinib is a positive for the shares. We also believe that pipeline updates for RXDX-105, a BRAF/EGFR/RET inhibitor in Phase Ib, and RXDX-106, a Tyro-3/Axl/Mer (TAM) inhibitor in Phase I, could also be valuation drivers for the shares. Valuation and EPS. We have updated our model and are introducing our 2017 quarterly EPS forecasts." (4/28/2017)
  • 3. Jefferies Group LLC analysts commented, "ENA preclinical posters on RXDX-106 showed encouraging activity in both immuno-oncologic modulation and direct tumor targeting. These initial data support further development of ‘106 and we would look for more details at Dec 1 conference call. Incremental preclinical data of ‘105 and entrectinib were also presented." (11/30/2016)

Who are some of Ignyta's key competitors?

Who are Ignyta's key executives?

Ignyta's management team includes the folowing people:

  • Jonathan E. Lim M.D., Chairman of the Board, President, Chief Executive Officer, Co-Founder
  • Jacob M. Chacko M.D., Chief Financial Officer
  • Zachary Hornby, Chief Operating Officer
  • Valerie Harding Start Ph.D., Senior Vice President - Chemistry, Manufacturing, and Controls
  • Christian V. Kuhlen M.D. Esq., General Counsel, Secretary
  • William R. McCarthy, Chief Business Officer
  • Pratik S. Multani M.D., Chief Medical Officer
  • James A. Bristol Ph.D., Independent Director
  • Alexander W. Casdin, Independent Director
  • Heinrich Dreismann Ph.D., Independent Director

Who owns Ignyta stock?

Ignyta's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Tang Capital Management LLC (8.47%), RA Capital Management LLC (7.14%), Victory Capital Management Inc. (8.70%), Broadfin Capital LLC (5.23%), Frazier Management LLC (3.86%) and Vanguard Group Inc. (4.25%). Company insiders that own Ignyta stock include Alexander W Casdin, Jacob Chacko, James A Bristol, James L Freddo and Jonathan E Lim. View Institutional Ownership Trends for Ignyta.

Who sold Ignyta stock? Who is selling Ignyta stock?

Ignyta's stock was sold by a variety of institutional investors in the last quarter, including PointState Capital LP, Nexthera Capital LP, JPMorgan Chase & Co., Artal Group S.A., FMR LLC and Dimensional Fund Advisors LP. View Insider Buying and Selling for Ignyta.

Who bought Ignyta stock? Who is buying Ignyta stock?

Ignyta's stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management LLC, Emerald Advisers Inc. PA, Frazier Management LLC, Emerald Mutual Fund Advisers Trust, Farallon Capital Management LLC, Victory Capital Management Inc., Tang Capital Management LLC and Pier Capital LLC. Company insiders that have bought Ignyta stock in the last two years include Alexander W Casdin, Jacob Chacko, James A Bristol, James L Freddo and Jonathan E Lim. View Insider Buying and Selling for Ignyta.

How do I buy Ignyta stock?

Shares of Ignyta can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ignyta's stock price today?

One share of Ignyta stock can currently be purchased for approximately $12.10.


MarketBeat Community Rating for Ignyta (NASDAQ RXDX)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  157 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  234
MarketBeat's community ratings are surveys of what our community members think about Ignyta and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ignyta (NASDAQ:RXDX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.00 (73.55% upside)

Analysts' Ratings History for Ignyta (NASDAQ:RXDX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/6/2017Cantor FitzgeraldReiterated RatingBuy$15.00LowView Rating Details
6/22/2017Jefferies Group LLCReiterated RatingBuy -> Buy$27.00HighView Rating Details
8/10/2016Piper Jaffray CompaniesLower Price TargetOverweight$32.00 -> $20.00N/AView Rating Details
7/12/2016Credit Suisse GroupReiterated RatingBuyN/AView Rating Details
6/23/2016J P Morgan Chase & CoInitiated CoverageOverweight$15.00N/AView Rating Details
5/12/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for Ignyta (NASDAQ:RXDX)
Earnings by Quarter for Ignyta (NASDAQ:RXDX)
Earnings History by Quarter for Ignyta (NASDAQ RXDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.63)($0.56)ViewN/AView Earnings Details
5/1/2017Q1 2017($0.69)($0.96)ViewN/AView Earnings Details
11/7/2016Q3 2016($0.67)($0.56)ViewN/AView Earnings Details
5/10/2016Q1($0.68)($0.79)ViewListenView Earnings Details
3/14/2016Q415($0.57)($1.32)ViewN/AView Earnings Details
11/9/2015Q315($0.60)($0.49)ViewN/AView Earnings Details
8/10/2015Q215($0.65)($0.51)ViewListenView Earnings Details
5/11/2015Q115($0.79)($1.15)ViewListenView Earnings Details
4/14/2015($0.79)($1.05)ViewN/AView Earnings Details
3/17/2015Q414($0.59)($2.18)ViewN/AView Earnings Details
11/7/2014Q314$0.01($0.55)$215.50 millionViewN/AView Earnings Details
8/12/2014($0.26)($0.28)$0.15 millionViewN/AView Earnings Details
5/12/2014($0.37)($0.28)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ignyta (NASDAQ:RXDX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.69)($0.69)($0.69)
Q3 20171($0.53)($0.53)($0.53)
Q4 20171($0.55)($0.55)($0.55)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ignyta (NASDAQ:RXDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ignyta (NASDAQ:RXDX)
Insider Ownership Percentage: 13.08%
Institutional Ownership Percentage: 80.82%
Insider Trades by Quarter for Ignyta (NASDAQ:RXDX)
Institutional Ownership by Quarter for Ignyta (NASDAQ:RXDX)
Insider Trades by Quarter for Ignyta (NASDAQ:RXDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2016James A BristolDirectorBuy5,000$5.65$28,250.00View SEC Filing  
5/4/2016Alexander W CasdinDirectorBuy232,000$6.25$1,450,000.00View SEC Filing  
3/17/2016Jacob ChackoCFOBuy10,000$5.64$56,400.00View SEC Filing  
3/17/2016James L FreddoDirectorBuy3,000$5.39$16,170.00View SEC Filing  
3/17/2016Jonathan E LimCEOBuy24,852$5.51$136,934.52View SEC Filing  
12/16/2015Jacob ChackoCFOBuy1,500$12.00$18,000.00View SEC Filing  
8/20/2015City Hill Venture Partners I,major shareholderBuy8,480$12.90$109,392.00View SEC Filing  
6/15/2015Robert WildVPBuy1,200$16.35$19,620.00View SEC Filing  
3/20/2015Jonathan E LimCEOBuy20,000$9.01$180,200.00View SEC Filing  
3/17/2015Alexander W CasdinDirectorBuy408,750$10.00$4,087,500.00View SEC Filing  
11/24/2014Jacob ChackoCFOBuy1,598$6.46$10,323.08View SEC Filing  
8/19/2014Jacob ChackoCFOBuy1,840$7.53$13,855.20View SEC Filing  
8/15/2014Jonathan E LimCEOBuy5,000$7.60$38,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ignyta (NASDAQ:RXDX)
Latest Headlines for Ignyta (NASDAQ:RXDX)
Source:
DateHeadline
finance.yahoo.com logoIgnyta to Present at Cantor Fitzgerald 2017 Global Healthcare Conference
finance.yahoo.com - September 20 at 8:37 AM
finance.yahoo.com logoIgnyta to Present at the Ladenburg Thalmann 2017 Healthcare Conference
finance.yahoo.com - September 19 at 7:21 AM
seekingalpha.com logoIgnyta: A Value-Catalyst Play - Seeking Alpha
seekingalpha.com - September 13 at 4:43 PM
reuters.com logoBRIEF-Ignyta provides update on entrectinib and RXDX-105 at the ESMO 2017 Congress
www.reuters.com - September 12 at 9:25 AM
finance.yahoo.com logoIgnyta Provides Update on Entrectinib and RXDX-105 at the ESMO 2017 Congress
finance.yahoo.com - September 12 at 9:25 AM
finance.yahoo.com logoIgnyta Announces Presentation of New Phase 1B Clinical Data on RXDX-105 in RET Fusion-Positive NSCLC at ESMO 2017 Congress
finance.yahoo.com - September 8 at 7:56 AM
americanbankingnews.com logoIgnyta's (RXDX) Buy Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - September 7 at 3:26 PM
streetinsider.com logoIgnyta (RXDX) Offers Regulatory Update on Entrectinib ROS1 Lung Cancer Development Program
www.streetinsider.com - September 7 at 8:40 AM
finance.yahoo.com logoIgnyta Provides Regulatory Update on Entrectinib ROS1 Lung Cancer Development Program
finance.yahoo.com - September 7 at 8:40 AM
zacks.com logoImplied Volatility Surging for Ignyta (RXDX) Stock Options
www.zacks.com - September 6 at 7:56 AM
finance.yahoo.com logoIgnyta to Host Conference Call and Webcast on Entrectinib ROS1 Lung Cancer Update on September 6, 2017
finance.yahoo.com - August 31 at 9:37 AM
americanbankingnews.com logoContrasting Fate Therapeutics (FATE) & Ignyta (RXDX)
www.americanbankingnews.com - August 19 at 4:32 PM
finance.yahoo.com logoIgnyta Reports Granting of Inducement Awards
finance.yahoo.com - August 19 at 7:13 AM
americanbankingnews.com logoZacks Investment Research Upgrades Ignyta, Inc. (RXDX) to "Hold"
www.americanbankingnews.com - August 15 at 9:56 AM
americanbankingnews.com logoJefferies Group Weighs in on Ignyta, Inc.'s Q3 2017 Earnings (NASDAQ:RXDX)
www.americanbankingnews.com - August 14 at 2:28 AM
americanbankingnews.com logoIgnyta, Inc. Expected to Post FY2021 Earnings of $1.84 Per Share (NASDAQ:RXDX)
www.americanbankingnews.com - August 11 at 5:22 PM
americanbankingnews.com logoIgnyta, Inc. (RXDX) Posts Earnings Results, Beats Estimates By $0.07 EPS
www.americanbankingnews.com - August 9 at 4:46 PM
finance.yahoo.com logoIgnyta Announces Second Quarter 2017 Company Highlights and Financial Results
finance.yahoo.com - August 9 at 7:08 AM
finance.yahoo.com logoIgnyta reports 2Q loss
finance.yahoo.com - August 9 at 7:08 AM
americanbankingnews.com logo-$0.61 EPS Expected for Ignyta, Inc. (RXDX) This Quarter
www.americanbankingnews.com - August 5 at 7:08 AM
americanbankingnews.com logoIgnyta, Inc. (RXDX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - July 29 at 12:31 PM
seekingalpha.com logo2 Small Oncology Stocks That Could Rally Through Year-End - Seeking Alpha
seekingalpha.com - July 22 at 8:28 AM
seekingalpha.com logoIgnyta Lights The Fire - Seeking Alpha
seekingalpha.com - July 22 at 8:28 AM
americanbankingnews.com logoIgnyta, Inc. (RXDX) Downgraded by BidaskClub to Buy
www.americanbankingnews.com - July 19 at 7:28 PM
americanbankingnews.com logoIgnyta, Inc. (NASDAQ:RXDX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 19 at 6:46 PM
nasdaq.com logo4 Sell-Ranked Drug Stocks to Avoid Ahead of Q2 Earnings - Nasdaq
www.nasdaq.com - July 17 at 3:36 PM
americanbankingnews.com logoIgnyta Inc (NASDAQ:RXDX) Expected to Announce Earnings of -$0.61 Per Share
www.americanbankingnews.com - July 13 at 10:18 PM
prnewswire.com logoStock Performance Review on Biotech Industry -- Athersys, AVEO Pharma, Heat Biologics, and Ignyta - PR Newswire (press release)
www.prnewswire.com - July 13 at 9:00 AM
finance.yahoo.com logoIgnyta Receives FDA Orphan Drug Designation for Entrectinib for Treatment of NTRK Fusion-Positive Solid Tumors
finance.yahoo.com - July 11 at 7:20 AM
americanbankingnews.com logoZacks Investment Research Downgrades Ignyta, Inc. (NASDAQ:RXDX) to Sell
www.americanbankingnews.com - July 4 at 7:22 AM
americanbankingnews.com logoIgnyta, Inc. (RXDX) Short Interest Up 167.4% in June
www.americanbankingnews.com - June 30 at 7:06 AM
americanbankingnews.com logoQ2 2017 Earnings Forecast for Ignyta, Inc. (RXDX) Issued By Jefferies Group
www.americanbankingnews.com - June 26 at 7:10 AM
americanbankingnews.com logoIgnyta, Inc. (RXDX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - June 23 at 10:38 PM
americanbankingnews.com logoIgnyta, Inc. (RXDX) to Post FY2021 Earnings of $2.02 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - June 23 at 1:26 PM
streetinsider.com logoUPDATE: Jefferies Assumes Ignyta, Inc (RXDX) at Buy - StreetInsider.com
www.streetinsider.com - June 23 at 9:44 AM
americanbankingnews.com logoIgnyta, Inc. (RXDX) Coverage Initiated by Analysts at Jefferies Group LLC
www.americanbankingnews.com - June 22 at 11:02 AM
americanbankingnews.com logoIgnyta, Inc. (RXDX) Expected to Post Earnings of -$0.52 Per Share
www.americanbankingnews.com - June 19 at 10:26 PM
americanbankingnews.com logoIgnyta, Inc. (RXDX) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - June 15 at 8:10 PM
americanbankingnews.com logoCantor Fitzgerald Reiterates $15.00 Price Target for Ignyta Inc (RXDX)
www.americanbankingnews.com - June 5 at 8:42 PM
finance.yahoo.com logoIgnyta to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 1 at 8:20 AM
americanbankingnews.com logoIgnyta Inc (RXDX) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - May 30 at 9:32 PM
americanbankingnews.com logoIgnyta Inc (RXDX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 29 at 8:50 PM
americanbankingnews.com logoIgnyta Inc (RXDX) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - May 27 at 8:16 PM
americanbankingnews.com logoIgnyta Inc (RXDX) Sees Large Increase in Short Interest
www.americanbankingnews.com - May 27 at 8:58 AM
streetinsider.com logoIgnyta (RXDX) Granted FDA Breakthrough Therapy Designation for Entrectinib
www.streetinsider.com - May 15 at 6:52 PM
americanbankingnews.com logoCantor Fitzgerald Analysts Give Ignyta Inc (RXDX) a $15.00 Price Target
www.americanbankingnews.com - May 15 at 3:14 PM
finance.yahoo.com logoIgnyta Granted Breakthrough Therapy Designation for Entrectinib by U.S. Food and Drug Administration
finance.yahoo.com - May 15 at 9:32 AM
americanbankingnews.com logoResearch Analysts Issue Forecasts for Ignyta Inc's FY2017 Earnings (RXDX)
www.americanbankingnews.com - May 11 at 10:52 AM
finance.yahoo.com logoIgnyta Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - May 9 at 7:09 PM
streetinsider.com logoIgnyta (RXDX) Prices 12.5M Common Stock Offering at $6.15/Share
www.streetinsider.com - May 4 at 8:58 AM

Social

Chart

Ignyta (RXDX) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff